Invasive meningococcal disease morbidity and mortality persist among adolescents and infants in the United States

Currently, meningococcal vaccination covering serogroups ACWY (MenACWY) is routinely recommended for all adolescents 11−12 years of age, with a booster dose at 16 years of age, and meningococcal serogroup B (MenB) vaccination is recommended for persons 16−23 years of age under the shared clinical decision-making framework

A pentavalent meningococcal vaccine covering serogroups A, B, C, W, and Y (MenABCWY) is being investigated in healthy persons ≥ 10–25 years of age

The addition of a MenABCWY vaccine to the immunization schedule warrants consideration because it could simplify the schedule and increase uptake, which may reduce cases of invasive meningococcal disease, long-term sequelae, and costs associated with outbreaks

A MenABCWY vaccine would also reduce the number of injections required for adolescents, potentially improving compliance